A5032566622- Pulmonary Hypertension Research and Treatments
- Cardiac Fibrosis and Remodeling
- Peptidase Inhibition and Analysis
- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
Beijing Chaoyang Emergency Medical Center
2022-2025
Capital Medical University
2022-2025
Beijing Chao-Yang Hospital
2025
Background Myocardial fibrosis contributes to adverse cardiovascular events in hypertrophic cardiomyopathy (HCM). Purpose To explore the characteristics of cardiac fibroblast activation protein inhibitor (FAPI) PET/CT imaging and its relationship with risk sudden death (SCD) HCM. Materials Methods In this prospective study from July 2021 January 2022, participants HCM healthy control underwent fluorine 18 (18F)-labeled FAPI imaging. activity was quantified as intensity (target-to-background...
This retrospective study was designed to explore the relationship between right ventricular fibroblast activation measured by protein inhibitor (FAPI) imaging and myocardial deformation Speckle‑tracking Echocardiography (STE) in patients with pulmonary hypertension (PH). Clinical data of PH were collected [15 chronic thromboembolic (CTEPH), 4 PAH, 1 unclear and/or multifactorial mechanisms]. All underwent FAPI echocardiography within one month. activity ventricle higher than that blood pool...
The newly developed nanobody-based SPECT radiotracer, technetium 99m–labeled nanobody ( 99m Tc-AFN), noninvasively monitored fibroblast activation after myocardial infarction in preclinical models, supporting its potential use clinical imaging.